MannKind Corporation
biopharmaceutical company
MNKD Nasdaq
ISIN US56400P7069 SEC CIK 899460 LEI 213800GFBCNY1ZFST722
Follow MannKind
Weekly email: filings, results
Revenue, last quarter
$101.9M
+24% vs same quarter last year
Net income
−$23.2M
−390.8% vs same quarter last year
EPS, diluted
−$0.07
−333.3% vs same quarter last year
Operating cash flow
−$34.5M
−246.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $349M | $5.9M |
| FY24 | $285.5M | $27.6M |
| FY23 | $199M | −$11.9M |
| FY22 | $99.8M | −$87.4M |
| FY21 | $75.4M | −$80.9M |
| FY20 | $65.1M | −$57.2M |
| FY19 | $63M | −$51.9M |
| FY18 | $27.9M | −$87M |
| FY17 | $11.7M | −$117.3M |
| FY16 | $174.8M | $125.7M |
| FY15 | $0 | −$368.4M |
| FY14 | $0 | −$198.4M |
| FY13 | $0 | −$191.5M |
| FY12 | $35K | −$169.4M |
| FY11 | $50K | −$160.8M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 92.3% | 11.1% | 1.7% |
| FY24 | 93.9% | 25.4% | 9.7% |
| FY23 | 89.5% | 4.4% | −6% |
| FY22 | 84% | −64.3% | −87.6% |
| FY21 | 77.7% | −62.3% | −107.3% |
| FY20 | 76.8% | −73.5% | −87.9% |
| FY19 | 68.1% | −70.7% | −82.3% |
| FY18 | 30.4% | −274.9% | −312.2% |
| FY17 | −46.7% | −921.1% | −999% |
| FY16 | 90.2% | 38.5% | 71.9% |
| FY15 | - | - | - |
| FY14 | - | - | - |
| FY13 | - | - | - |
| FY12 | - | −419885.7% | −483902.9% |
| FY11 | - | −281078% | −321608% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $13.7M |
| FY24 | $32.8M |
| FY23 | −$8.3M |
| FY22 | −$88.3M |
| FY21 | −$73.2M |
| FY20 | −$28.9M |
| FY19 | −$91M |
| FY18 | −$38.1M |
| FY17 | - |
| FY16 | −$79.2M |
| FY15 | −$67.5M |
| FY14 | −$20M |
| FY13 | −$136.7M |
| FY12 | −$120.5M |
| FY11 | −$130.7M |
- MannKind
- Healthcare median
Show the numbers
| Year | MannKind | Healthcare median |
|---|---|---|
| FY25 | 1.7% | −30.6% |
| FY24 | 9.7% | −47% |
| FY23 | −6% | −58% |
| FY22 | −87.6% | −80.4% |
| FY21 | −107.3% | −71.8% |
| FY20 | −87.9% | −62.2% |
| FY19 | −82.3% | −46.2% |
| FY18 | −312.2% | −49.6% |
| FY17 | −999% | −45.9% |
| FY16 | 71.9% | −36% |
| FY15 | - | −37.8% |
| FY14 | - | −35.5% |
| FY13 | - | −37.1% |
| FY12 | −483902.9% | −29.1% |
| FY11 | −321608% | −27.9% |